BR112013010836A2 - inibidores específicos de ns3 protease de hcv - Google Patents

inibidores específicos de ns3 protease de hcv

Info

Publication number
BR112013010836A2
BR112013010836A2 BR112013010836A BR112013010836A BR112013010836A2 BR 112013010836 A2 BR112013010836 A2 BR 112013010836A2 BR 112013010836 A BR112013010836 A BR 112013010836A BR 112013010836 A BR112013010836 A BR 112013010836A BR 112013010836 A2 BR112013010836 A2 BR 112013010836A2
Authority
BR
Brazil
Prior art keywords
hcv
specific inhibitors
protease specific
protease
inhibitors
Prior art date
Application number
BR112013010836A
Other languages
English (en)
Portuguese (pt)
Inventor
Courcambeck Jerome
Bouzidi Mourad
Halfon Philippe
Anthony Whitaker Richard
J Coats Steven
Original Assignee
Genoscience Pharma
Rfs Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma, Rfs Pharma Llc filed Critical Genoscience Pharma
Publication of BR112013010836A2 publication Critical patent/BR112013010836A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112013010836A 2010-11-01 2011-10-28 inibidores específicos de ns3 protease de hcv BR112013010836A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40898910P 2010-11-01 2010-11-01
PCT/US2011/058404 WO2012061248A2 (en) 2010-11-01 2011-10-28 Novel specific hcv ns3 protease inhibitors

Publications (1)

Publication Number Publication Date
BR112013010836A2 true BR112013010836A2 (pt) 2019-09-24

Family

ID=46025037

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010836A BR112013010836A2 (pt) 2010-11-01 2011-10-28 inibidores específicos de ns3 protease de hcv

Country Status (10)

Country Link
US (1) US8729014B2 (https=)
EP (1) EP2635570B1 (https=)
JP (1) JP5828903B2 (https=)
CN (1) CN103328466B (https=)
AU (1) AU2011323658A1 (https=)
BR (1) BR112013010836A2 (https=)
CA (1) CA2815855C (https=)
IL (1) IL225908A0 (https=)
MX (1) MX2013004906A (https=)
WO (1) WO2012061248A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
BR112016023833A2 (pt) * 2014-04-15 2017-10-10 Cocrystal Pharma Inc compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c
CN105315261A (zh) * 2014-08-04 2016-02-10 正大天晴药业集团股份有限公司 Hcv ns3蛋白酶抑制剂的钠盐

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000536A1 (en) 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0412502A (pt) 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
JP4902361B2 (ja) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006111906A2 (en) 2005-04-19 2006-10-26 Philips Intellectual Property & Standards Gmbh Illumination system comprising a red-emitting ceramic luminescence converter
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CN101495457A (zh) * 2006-07-05 2009-07-29 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
CN101553170B (zh) 2006-11-24 2011-11-09 株式会社岛津制作所 X射线透视摄影装置
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CA2710144A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
EA201071034A1 (ru) 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
AU2011209051B2 (en) * 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
JP5828903B2 (ja) 2015-12-09
EP2635570A2 (en) 2013-09-11
US8729014B2 (en) 2014-05-20
EP2635570A4 (en) 2014-04-16
CN103328466A (zh) 2013-09-25
US20120129765A1 (en) 2012-05-24
AU2011323658A1 (en) 2013-05-23
WO2012061248A2 (en) 2012-05-10
CN103328466B (zh) 2016-08-03
MX2013004906A (es) 2013-12-06
WO2012061248A3 (en) 2012-08-02
EP2635570B1 (en) 2017-12-13
JP2013542955A (ja) 2013-11-28
CA2815855C (en) 2016-02-02
CA2815855A1 (en) 2012-05-10
WO2012061248A8 (en) 2013-08-01
IL225908A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
HUS1700039I1 (hu) Makrociklusos prolinból leszármaztatható HCV szerin proteáz inhibitorok
EP2618665A4 (en) HCV NS3 proteinase inhibitor
EP2271345A4 (en) HCV NS3 proteinase inhibitor
BRPI0923184A2 (pt) inibidores de hcv ns3 protease
DK2373172T3 (da) Hcv-ns5a-hæmmere
EP2477980A4 (en) HCV Protease Inhibitors
EP2575866A4 (en) HCV NS5A INHIBITORS
EP2780026A4 (en) HCV NS3 proteinase inhibitor
EP2575475A4 (en) HCV NS5A INHIBITORS
ZA201008988B (en) Hcv protease inhibitors
EP2398474A4 (en) HCV NS5A SHEMMER
BR112012005438A2 (pt) inibidores de vírus flaviviridae
EP2740734A4 (en) HCV Protease Inhibitors
BRPI1014920A2 (pt) luva
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
EP2802574A4 (en) INHIBITORS OF HCV NS3 PROTEASE
BRPI1011267A2 (pt) inibidores de protease
EP2432318A4 (en) NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
BR112013010836A2 (pt) inibidores específicos de ns3 protease de hcv
BRPI1010661A2 (pt) peptídeo
BRPI0918966A2 (pt) inibidores de protease
BR112013008510A2 (pt) vitamina e formulações de inibidores de sulfamida ns3
BRPI0919073A2 (pt) inibidores de protease
HK1188456A (en) Novel specific hcv ns3 protease inhibitors
TH0901005440A (th) ตัวยับยั้งของ hcv ns5a

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.